



**The Evolution of Immunotherapy:
An Exploration of Immunity Beyond T cells,
CAR T in Solid Tumors and Novel Combinations
Abstract Guide**

Wednesday, Nov. 10, 2021

SITC 2021 The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations Abstract Guide

Table of Contents

The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations Program Overview	1
Program Purpose	1
Program Organizers	1
Target Audience	1
Learning Objectives	2
Reasons to Submit an Abstract	2
Abstract Submission Information	3
Submitting an Abstract	3
Abstract Submission Deadline	3
Abstract Submission Criteria	3
Application	4
Important Abstract Dates	5
Abstract Guidelines	6
Submission Guidelines	6
Annual Meeting Abstract Submission	6
Abstract Presentation Information	7
Abstract Presentation Guidelines	7
Faculty Guidelines and Information	7
Abstract Policies	9
Press Release Policy	9
Withdrawal and Editing Policy	9

The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations Program Overview

The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations is part of SITC's 36th Annual Meeting & Pre-Conference Programs (SITC 2021) and will be held on Nov. 10, 2021.

Program Purpose

It has been a decade since the first approval of an immune checkpoint inhibitor. In the ten years since, the field of cancer immunotherapy has seen unprecedented growth. In order to further improve patient outcomes, cancer immunotherapy approaches are constantly evolving. This program will discuss three key areas for the future of cancer immunotherapy: immunity beyond T cells, the application of CAR T therapy in solid tumors, and novel immunotherapy combinations. Addressing these key areas will help the next ten years of immunotherapy be as successful as the last.

Program Organizers

This program is organized in collaboration with the SITC Industry Committee. The following individuals are recognized for their leadership in developing this program:

- Kald Abdallah, MD, PhD – *Bristol Myers Squibb*
- Jennifer Gansert, MD, PhD – *Amgen*
- Mary Margaret Huizinga, MD, MPH, FACP – *Novartis Pharmaceuticals*
- Francesco M. Marincola, MD – *Kite, A Gilead Company*
- Giovanni Melillo, MD – *AstraZeneca*
- Zhen Su, MD, PhD – *EMD Serono*

Target Audience

The target audience for this program includes researchers from academia and industry involved in basic, translational and clinical cancer research, as well as clinicians and those from regulatory and funding agencies.

Learning Objectives

At the conclusion of this activity, participants should be able to:

- Outline the role of immune cells other than T cells in anti-cancer immunity
- Summarize the state of CAR T application in solid tumors and future directions for this field
- Discuss the rational combination of immunotherapies with other anti-cancer modalities to improve patient outcomes

Reasons to Submit Your Abstract to the Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations Program

- Multiple oral presentation opportunities available
- The opportunity to present and discuss your research with luminaries in the immunotherapy field
- Addressing these key topics/areas will continue to help the field of immunotherapy in the coming years

Abstract Submission Information

Submitting an Abstract

Industry and academic investigators who are working on immunity beyond T cells, the application of CAR T therapy in solid tumors, or novel immunotherapy combinations are welcome to submit an abstract describing their research for the opportunity to present during The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations Pre-Conference Program.

To submit an abstract please click [here](#).

Abstract Submission Deadline

August 19, 2021 by 5 p.m. PDT: Deadline to submit abstracts.

Abstract Submission Criteria

Abstract reviewers consider a number of variables in reviewing and selecting the abstracts for presentation, including, but not limited to, the following criteria:

- Quality of the research and presentation
- Strength of the results and methods
- Whether the reported research significantly advances the field
- Content in your presentation must be available to publicly present by Nov. 10, 2021

The abstracts will be reviewed and scored by a select group of members from the SITC Industry Committee. Following the review and scoring of the abstracts, they are forwarded to the Co-Chairs of the Industry Committee for their review. A call is then scheduled to select the abstracts to be presented at the program.

Please Note: Abstracts for The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations will **NOT** be published in the *Journal for ImmunoTherapy of Cancer (JITC)*, only posted on the SITC website.

Abstracts should address one of the following topics:

- Immunity Beyond T cells
- CAR T and other Cell Therapies in Solid Tumors
- Novel Combinations

Preference will be given to abstract submissions with the following:

- Has minimal overlap with other abstract
- Has not been presented elsewhere or has significant changes to the submission since last being presented/published
- Has clinical or translational data

Application

Please provide a description of your research and results, limited to one page, including the following sections:

- Background
- Methods
- Results
- Conclusion

Important Abstract Dates

End of June	Abstract submission site opens for The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations
August 19, 2021	Abstract submission site closes for The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations
September 24, 2021	Abstract notifications sent for The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations
October 1, 2021	Accepted abstract confirmations due and deadline for withdrawals and changes for The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations
October 1, 2021	Presenter Information and Registration for Accepted Abstracts Due
October 14, 2021	Presentation Slides and Recording Permission for Accepted Abstract Presenters Due
November 10, 2021	The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations Pre-Conference Program
November 10-14, 2021	36 th Annual Meeting & Pre-Conference Programs

Abstract Guidelines

Submission Guidelines for The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations

Below are the guidelines for abstract submission for The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations. The submitting author is responsible for assuring that the abstract adheres to these.

Title

The title should be entered exactly as it should appear in the program. Do not put the title in quotes, underline it, or put periods at the end. The title can be a maximum of 200 characters, including spaces.

Example: Novel Pharmacologic Approach to Enhance the Epigenetic and Immune Priming Effect of Decitabine in Patients with Advanced Non-small cell Lung Cancer

Presenters

Submitters will be asked to include information about the presenter if the abstract is accepted for presentation. Please enter the information about the presenter.

- If the abstract submitter will be the presenter, the submitter can simply update their role by clicking on “Submitter Only,” selecting “Presenter” and clicking *Save*.
- If the submitter will not be the presenter, the submitter should keep “Submitter Only” as their Role and click “Add Person” to add the presenter

Annual Meeting Abstract Submission

Please note, abstracts submitted for The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations **DO NOT** qualify as a 36th Annual Meeting abstract submission; however, you may submit your work to both programs by completing both an The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations Program abstract submission and an Annual Meeting abstract submission. If you are interested in submitting your work as a formal abstract to the 36th Anniversary Annual Meeting, Nov. 10-14, 2021, you can do so by going to <https://www.sitcancer.org/2021/abstracts/abstract-information>.

Abstract Presentation Information

After abstracts are reviewed and selected, abstract submitters will be sent an email notification stating whether the abstract was accepted. Within the notification for accepted abstracts, the abstract submitter will also be asked to accept or decline participation in the Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations program. If we do not receive a response by October 1, 2021 we will assume you accept and will present.

Presentation Guidelines

Registration

The presenter must register for The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations program to present. Submitting an abstract does not register them for the meeting.

Abstract Presentations

All abstracts chosen for presentation will present on Wednesday, Nov. 10. Abstracts are 10-15 minutes long.

The designated abstract presenter will be added to the SITC speaker management system upon confirming participation in the program to collect all required information. Abstract presenters will be required to submit a conflict of disclosure form, a recording permission form, a photo, and a biography as well as submit presentation slides prior to the program.

Prior to the program, all presenters will be contacted with the final program information so that they may communicate with their moderating Organizer and other presenters. Some Organizers may schedule a conference call to review the presentations and group discussions, others may communicate via email. All presenters are required to be responsive to the requests of the program Organizers and SITC staff.

Faculty Guidelines and Information

Guidelines

Please take into consideration the following guidelines when creating and presenting your talk for this educational activity. These guidelines were created to help ensure that presentations give a balanced viewpoint to learners that is free of commercial bias.

- Faculty will disclose to SITC all relevant financial relationships, and hereby allow SITC to disclose this information to learners in print.
- Presentations and/or content will need to be reviewed prior to the activity. Educational content and resources must be submitted in advance. Presentations/content is due Oct. 14.
- The content and/or presentation of the information with which you are involved, including any presentation of therapeutic options, is expected to be well-balanced, evidence-based and unbiased. It will promote quality or improvements in healthcare and will not promote a specific proprietary business interest of a commercial interest.

- If faculty are presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.
- If faculty have been trained or utilized by a commercial entity or its agent as a speaker (i.e., speaker's bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.
- If faculty provide recommendations involving clinical medicine, they will be based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients. All scientific research relating to this activity in support of a patient care recommendation will conform to the generally accepted standards of experimental design, data collection, and analysis.
- If faculty discuss specific health care products or services, they are to use generic names to the extent possible. If necessary to mention trade names, faculty will use trade names from several different companies when available.
- If faculty discuss any product use that is off-label or investigational, they are to disclose that the use or indication in question is not currently approved by the FDA. Please state in presentations, "There **will OR will not** be discussion about the use of products for non-FDA approved indications in this presentation."
- Faculty have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with SITC specific to this particular presentation for the SITC educational activity.
- A monitor will be attending the event to ensure that all presentations are educational, and not promotional, in nature.

Faculty Information

- Faculty Resource Room: A Faculty Resource Room will be available onsite during the 36th Annual Meeting & Pre-Conference Programs for presenters to upload updated slides. All faculty are required to load final presentation slides at least 2 hours before the start of the program in which they are presenting (day before preferred) in the Faculty Resource Room. Due to CME review of slides for some sessions, there may be a wait time for uploading your slides. Please plan accordingly. We will do everything we can to make wait times brief, but your patience with the process will be appreciated.
- Presentation Requirements: All presentations must be in 16:9 aspect ratio. All Faculty must also have a disclosure slide in the beginning of their presentation, even if just to state that there are no relevant disclosures to the presentation. If faculty intend to discuss any product use that is off-label or investigational, they must disclose that the use or indication in question is not currently approved by the FDA. Faculty must include the following sentence on their disclosure slide: "There **will OR will not** be discussion about the use of products for non-FDA approved indications in this presentation." Please use the 36th Annual Meeting slide template for creating your PowerPoint presentation.
- Recording Permissions: To advance the field, SITC requests you complete a recording permission form to give us permission to post your slides on the Society's website and/or to prepare audio-visual (AV) recordings of your presentation for production, online hosting, and distribution as webinars and/or other electronic media. These enduring materials greatly extend the educational impact and reach of the live meeting.

Abstract Policies

Below are the policies of the SITC, The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations program abstract submission process. By submitting an abstract, you are agreeing to abide by these policies.

Press Release Policy

Any planned press releases and media alerts must be reviewed and approved in advance by SITC Communications staff. Please provide a minimum of two business days for review. Drafts should be emailed to communications@sitcancer.org.

Withdrawal & Editing Policy

The deadline for abstract withdrawal or changes, including presenter changes, is October 1, 2021. If you would like to withdraw or make a change to your abstract between the submission deadline and this date, you must submit your request in writing to education@sitcancer.org. Upon receipt of your request we will make the change, if possible, and send a confirmation once the withdrawal or change has been completed.